The Experts below are selected from a list of 2184 Experts worldwide ranked by ideXlab platform
M G Lebwohl - One of the best experts on this subject based on the ideXlab platform.
-
Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy
Journal of drugs in dermatology : JDD, 2018Co-Authors: Emil Tanghetti, M G Lebwohl, Linda Stein GoldAbstract:Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Treatment options focus on relieving symptoms, reducing inflammation, induration, and scaling, and controlling the extent of the disease. While significant data on Tazarotene in psoriasis has been available for over 20 years, its main utility is in acne. Objective: To review the clinical studies with Tazarotene in psoriasis and establish its future role in the management of this chronic, incurable condition. Methods: An English language literature review was performed utilizing Medline, EMBASE, and the Web of Science to identify relevant articles, both clinical trials and reviews. Results: Tazarotene is a very effective treatment for plaque psoriasis, with significant reductions in both plaque elevation and scaling after 12 weeks. Efficacy appears to be dose and formulation dependent, and erythema less responsive. Tazarotene sustains clinical response posttreatment and may have an important role in maintenance therapy. The most common side effect is mild-to-moderate local irritation, which limited its role as a single agent for psoriasis. Efficacy is enhanced through combination with topical corticosteroids (TCS). Tazarotene may circumvent the problem of TCS tachyphylaxis, due to its sustained efficacy and provide tolerability benefits; Tazarotene increases epidermal thickness and may reduce the risk of steroid-induced atrophy. In addition, Tazarotene-induced irritation is reduced by the anti-inflammatory effect of TCS. A new fixed combination, well-tolerated Tazarotene/halobetasol topical formulation is now available, which provides synergistic efficacy that is both rapid and sustained posttreatment. Conclusions: Tazarotene is a highly effective psoriasis treatment whose efficacy and tolerability can be enhanced through combination therapy with TCS, and a new fixed combination topical formulation of Tazarotene and halobetasol may provide an optimal management approach. J Drugs Dermatol. 2018;17(12):1280-1287.
-
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of Tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Journal of the American Academy of Dermatology, 2003Co-Authors: Gerald D. Weinstein, John R. Gibson, John Sefton, Nicholas J. Lowe, Gerald G. Krueger, M G Lebwohl, John Koo, Deborah A. Lew-kaya, M. Alan Menter, Patricia S. WalkerAbstract:Abstract Background: Tazarotene in a gel formulation is widely used in the treatment of psoriasis. Objective: To determine the efficacy and safety of Tazarotene 0.1% and 0.05% creams in the treatment of psoriasis. Methods: A total of 1303 patients participated in 2 clinical trials. Patients applied Tazarotene creams 0.1% and 0.05% or vehicle once daily to all psoriatic lesions for 12 weeks followed by a 12-week posttreatment period. Results: Both creams were significantly more effective than vehicle on the basis of an overall assessment of psoriasis, a global response to treatment, and reduction in plaque elevation and scaling. Therapeutic effect was maintained during the posttreatment period. Common adverse events included signs and symptoms of skin irritation. Conclusion: Tazarotene creams were associated with significant reductions in the severity of the clinical signs of psoriasis and were found to be safe with acceptable tolerability. Tazarotene cream 0.1% was generally more effective, although slightly less well tolerated, than the 0.05% cream. (J Am Acad Dermatol 2003;48:760-7.)
-
duration of improvement in psoriasis after treatment with Tazarotene 0 1 gel plus clobetasol propionate 0 05 ointment comparison of maintenance treatments
International Journal of Dermatology, 2001Co-Authors: M G Lebwohl, Kathleen LombardiAbstract:Fifty patients were enrolled in a double-blind, randomized, parallel-group study designed to determine whether Tazarotene may have a role in maintenance therapy for psoriasis. The patients had stable moderate-to-severe plaque psoriasis on up to 15% of their body surface area, on sites other than the face and scalp. Their mean age was 55 years and the majority had had psoriasis for more than 10 years. Washout periods were: 2 weeks for topical drugs, 4 weeks for UVB or PUVA treatment, and 8 weeks for systemic drugs that might alter the course of psoriasis. For the initial open-label treatment phase, patients applied Tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment for 6 weeks. The frequency of application of both medications was initially once daily and then was tapered to ensure gradual weaning. Thus, during weeks 1 and 2, patients applied Tazarotene each morning and clobetasol propionate each evening. During weeks 3 and 4, patients applied Tazarotene each morning and clobetasol propionate each Tuesday, Thursday, and Saturday evening. Finally, during weeks 5 and 6, patients applied Tazarotene each Monday, Wednesday, and Friday morning, and clobetasol propionate each Tuesday and Thursday evening. For the subsequent double-blind maintenance phase, patients were randomized to receive one of three maintenance regimens for 20 weeks – Tazarotene/clobetasol (Tazarotene 0.1% gel on Monday, Wednesday, and Friday mornings, plus clobetasol propionate 0.05% ointment on Tuesday and Thursday evenings), Tazarotene/vehicle (Tazarotene 0.1% gel on Monday, Wednesday, and Friday mornings, plus white petrolatum on Tuesday and Thursday evenings), and vehicle (Tazarotene gel vehicle on Monday, Wednesday, and Friday mornings plus white petrolatum on Tuesday and Thursday evenings). Patients were instructed to apply a thin film of medication to their psoriatic plaques. Emollient use was permitted, but other topical formulations and excessive exposure to ultraviolet light were not. Efficacy was evaluated – at baseline, every 2 weeks during the initial treatment phase, and every 4 weeks during the maintenance phase – in terms of overall disease severity, plaque elevation, scaling, erythema, pruritus, and global response to treatment. The first four of these were rated by the physician as 0 = none, 2 = mild, 4 = moderate, 6 = severe, and 8 = very severe. Pruritus was rated as 0 = none, 1 = trace, 2 = mild, 3 = moderate, 4 = marked, and 5 = severe. Global response was rated as 0 = cleared, 1 = almost cleared (∼90% improvement), 2 = marked (∼75%) improvement, 3 = moderate (∼50%) improvement, 4 = slight (∼25%) improvement, 5 = unchanged, and 6 = worse. Analysis of variance and the Student's t-test were used to compare maintenance regimens (P ≤ 0.05). In the maintenance phase, the last recorded score for each patient was carried forward to all subsequent visits.
-
strategies to optimize efficacy duration of remission and safety in the treatment of plaque psoriasis by using Tazarotene in combination with a corticosteroid
Journal of The American Academy of Dermatology, 2000Co-Authors: M G LebwohlAbstract:Abstract In the treatment of plaque psoriasis with corticosteroids, long-term efficacy and safety are often compromised by tachyphylaxis, steroid rebound, and adverse effects. However, the results of recent studies demonstrate that the use of Tazarotene in conjunction with a corticosteroid can help to optimize the efficacy, the duration of remission, and the safety of corticosteroid treatment. In one study, the adjunctive use of Tazarotene with a mid-potency corticosteroid promoted greater efficacy, more rapid efficacy, and more prolonged remission after treatment than corticosteroid monotherapy. In another study, after the induction of remission with Tazarotene plus a superpotent corticosteroid, maintenance therapy with Tazarotene, with or without the superpotent corticosteroid, achieved more sustained remissions than vehicle. In a third study, Tazarotene reduced the degree of epidermal atrophy induced by repeated applications of a superpotent corticosteroid on normal skin in healthy volunteers. (J Am Acad Dermatol 2000;43:S43-6.)
-
In vitro compatibility of Tazarotene with other topical treatments of psoriasis
Journal of the American Academy of Dermatology, 2000Co-Authors: David Hecker, John Worsley, Gene Yueh, M G LebwohlAbstract:Tazarotene is the first receptor-selective retinoid indicated for the topical treatment of plaque psoriasis. It is being used clinically in combination with other topical antipsoriatic treatments, although its stability in the presence of these products has not been examined extensively. This study examines the compatibility of Tazarotene 0.05% gel with 17 other topical products used in the treatment of psoriasis, assessed over a 2-week period. Tazarotene showed minimal degradation (
John R. Gibson - One of the best experts on this subject based on the ideXlab platform.
-
A multicenter, randomized, double-blind trial of Tazarotene 0.1% cream in the treatment of photodamage.
Journal of The American Academy of Dermatology, 2005Co-Authors: Sewon Kang, Deborah A. Lew-kaya, Patricia S. Walker, John Sefton, Emil Tanghetti, Gerald G. Krueger, John R. GibsonAbstract:Background Previous studies indicate that Tazarotene is efficacious in reducing signs of photodamage. Objective We sought to confirm the efficacy and tolerability of Tazarotene 0.1% cream in the treatment of facial photodamage. Methods A total of 568 patients with at least moderate fine wrinkling or mottled hyperpigmentation applied Tazarotene 0.1% cream or vehicle cream to their face once daily for 24 weeks. Results Tazarotene cream was significantly more effective than vehicle in reducing fine wrinkles, mottled hyperpigmentation, lentigines, irregular depigmentation, apparent pore size, elastosis, tactile roughness, and an overall integrated assessment of photodamage. Significance was achieved as early as week 2 for some parameters and had not plateaued by week 24. The majority of patients reported improvements in their photodamage as early as week 4. Adverse events were predominantly mild or moderate signs or symptoms of skin irritation. Conclusion Once-daily Tazarotene 0.1% cream is effective in ameliorating multiple signs of facial photodamage.
-
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of Tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Journal of the American Academy of Dermatology, 2003Co-Authors: Gerald D. Weinstein, John R. Gibson, John Sefton, Nicholas J. Lowe, Gerald G. Krueger, M G Lebwohl, John Koo, Deborah A. Lew-kaya, M. Alan Menter, Patricia S. WalkerAbstract:Abstract Background: Tazarotene in a gel formulation is widely used in the treatment of psoriasis. Objective: To determine the efficacy and safety of Tazarotene 0.1% and 0.05% creams in the treatment of psoriasis. Methods: A total of 1303 patients participated in 2 clinical trials. Patients applied Tazarotene creams 0.1% and 0.05% or vehicle once daily to all psoriatic lesions for 12 weeks followed by a 12-week posttreatment period. Results: Both creams were significantly more effective than vehicle on the basis of an overall assessment of psoriasis, a global response to treatment, and reduction in plaque elevation and scaling. Therapeutic effect was maintained during the posttreatment period. Common adverse events included signs and symptoms of skin irritation. Conclusion: Tazarotene creams were associated with significant reductions in the severity of the clinical signs of psoriasis and were found to be safe with acceptable tolerability. Tazarotene cream 0.1% was generally more effective, although slightly less well tolerated, than the 0.05% cream. (J Am Acad Dermatol 2003;48:760-7.)
-
efficacy of 0 1 Tazarotene cream for the treatment of photodamage a 12 month multicenter randomized trial
Archives of Dermatology, 2002Co-Authors: Tania J Phillips, Deborah A Lewkaya, Patricia S. Walker, John Sefton, Alice B. Gottlieb, James J. Leyden, Nicholas J. Lowe, John R. GibsonAbstract:Objective To determine the efficacy and safety of 0.1% Tazarotene cream for the treatment of photodamage. Design A 24-week multicenter, double-blind, randomized, vehicle-controlled intervention study followed by a 28-week open-label extension. Setting Ambulatory patients in private and institutional practice. Patients Of 563 patients with facial photodamage, 91% and 86% completed the double-blind and open-label phases, respectively. In the double-blind phase, 20 of 283 Tazarotene-treated patients and 1 of 280 vehicle-treated patients discontinued treatment owing to adverse events. Intervention Once-daily application of 0.1% Tazarotene cream or nonmedicated vehicle cream to the face for 24 weeks. Then, all continuing patients received treatment with 0.1% Tazarotene cream for another 28 weeks. Main Outcome Measures Primarily, fine wrinkling and mottled hyperpigmentation. Also, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, telangiectasia, actinic keratoses, overall integrated assessment of photodamage, global response to treatment, patients' overall assessment of photodamage, and plasma levels of tazarotenic acid. Results Compared with the vehicle, at week 24 Tazarotene resulted in a significantly greater incidence of patients achieving treatment success (≥50% global improvement) and at least a 1-grade improvement in fine wrinkling, mottled hyperpigmentation, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, and the overall integrated assessment of photodamage ( P Conclusions Once-daily applications of 0.1% Tazarotene cream significantly reduced multiple signs of photodamage. Plasma levels of tazarotenic acid remained below those of endogenous retinoids.
-
A pilot study to determine the effect of Tazarotene gel 0.1% on steroid-induced epidermal atrophy.
International journal of dermatology, 2001Co-Authors: Kays Kaidbey, John Sefton, Scott C. Kopper, John R. GibsonAbstract:Background Repeated applications of a corticosteroid can induce epidermal atrophy. This study was performed to investigate whether the adjunctive use of Tazarotene gel 0.1% might help to minimize the development of steroid-induced epidermal atrophy. Methods Each of 24 healthy volunteers received the following six treatments (applied 6 days per week for 4 weeks), which were randomized to each of six sites on their forearms: no treatment, Tazarotene vehicle, Tazarotene vehicle + Tazarotene gel 0.1%, diflorasone diacetate 0.05% ointment, diflorasone diacetate 0.05% ointment + Tazarotene vehicle, or diflorasone diacetate 0.05% ointment + Tazarotene gel 0.1%. Results The mean epidermal thickness was increased by 20% (NS) and 62% (P ≤ 0.0005) after applications of Tazarotene vehicle and Tazarotene gel 0.1%, respectively. Application of diflorasone diacetate reduced the mean epidermal thickness by 43% (P ≤ 0.0005). Concomitant application of Tazarotene gel 0.1% with diflorasone diacetate did not entirely prevent atrophy, but was shown to ameliorate 37% of the epidermal atrophy induced by diflorasone diacetate alone (P ≤ 0.003 compared with steroid monotherapy). Conclusions Tazarotene gel 0.1% significantly reduces epidermal atrophy induced by diflorasone diacetate 0.05% ointment.
-
photodamage pilot study a double blind vehicle controlled study to assess the efficacy and safety of Tazarotene 0 1 gel
Journal of The American Academy of Dermatology, 2000Co-Authors: John Sefton, Scott C. Kopper, Albert M Kligman, John C Lue, John R. GibsonAbstract:Abstract Background: Tazarotene, a potent acetylenic retinoid for topical use, might be expected to benefit photodamaged skin, including improving the classical signs of fine wrinkles, mottled hyperpigmentation, and roughness. Objective: Our purpose was to determine the efficacy and safety of Tazarotene 0.1% gel in the treatment of photodamaged dorsal forearm skin. Methods: Ten healthy female volunteers, aged 45 to 65 years, with moderately photodamaged forearm skin applied Tazarotene 0.1% gel to one arm and vehicle gel to the other once daily for 12 weeks. The study was a double-blind, randomized, paired-comparison evaluation conducted at a single site. Results: Tazarotene showed beneficial effects for several efficacy variables. It was more efficacious than vehicle in reducing skin roughness and fine wrinkling based on objective measurements. Tazarotene also corrected epidermal atrophy and atypia and improved skin hydration properties. Conclusion: In this 12-week pilot study Tazarotene redressed abnormalities associated with photo-damaged skin. (J Am Acad Dermatol 2000;43:656-63.)
Gerald D. Weinstein - One of the best experts on this subject based on the ideXlab platform.
-
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of Tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Journal of the American Academy of Dermatology, 2003Co-Authors: Gerald D. Weinstein, John R. Gibson, John Sefton, Nicholas J. Lowe, Gerald G. Krueger, M G Lebwohl, John Koo, Deborah A. Lew-kaya, M. Alan Menter, Patricia S. WalkerAbstract:Abstract Background: Tazarotene in a gel formulation is widely used in the treatment of psoriasis. Objective: To determine the efficacy and safety of Tazarotene 0.1% and 0.05% creams in the treatment of psoriasis. Methods: A total of 1303 patients participated in 2 clinical trials. Patients applied Tazarotene creams 0.1% and 0.05% or vehicle once daily to all psoriatic lesions for 12 weeks followed by a 12-week posttreatment period. Results: Both creams were significantly more effective than vehicle on the basis of an overall assessment of psoriasis, a global response to treatment, and reduction in plaque elevation and scaling. Therapeutic effect was maintained during the posttreatment period. Common adverse events included signs and symptoms of skin irritation. Conclusion: Tazarotene creams were associated with significant reductions in the severity of the clinical signs of psoriasis and were found to be safe with acceptable tolerability. Tazarotene cream 0.1% was generally more effective, although slightly less well tolerated, than the 0.05% cream. (J Am Acad Dermatol 2003;48:760-7.)
-
Tazarotene cream for the treatment of facial photodamage a multicenter investigator masked randomized vehicle controlled parallel comparison of 0 01 0 025 0 05 and 0 1 Tazarotene creams with 0 05 tretinoin emollient cream applied once daily for 24 we
Archives of Dermatology, 2001Co-Authors: Sewon Kang, Jean-paul Ortonne, Tania J Phillips, Deborah A Lewkaya, James J. Leyden, Nicholas J. Lowe, Jag Bhawan, Gerald D. Weinstein, Richard M MatsumotoAbstract:Objective To assess the safety and efficacy of 4 concentrations of Tazarotene cream in the treatment of facial photodamage. Design Prospective weekly multicenter, investigator-masked, randomized, parallel-group study. Setting University hospitals and clinical research centers. Patients Three hundred forty-nine subjects with facial photodamage. Intervention Daily topical application of Tazarotene cream (0.01%, 0.025%, 0.05%, and 0.1%) compared with its vehicle and with 0.05% tretinoin emollient cream. Results Tazarotene cream and tretinoin cream significantly improved mottled hyperpigmentation and fine wrinkles. At week 24, treatment success rates based on global responses were 67% (39 of 58 subjects) with 0.1% Tazarotene, 52% (30 of 58 subjects) with 0.05% Tazarotene, 36% (21 of 58 subjects) with 0.025% Tazarotene, 41% (24 of 59 subjects) with 0.01% Tazarotene, 55% (32 of 58 subjects) with 0.05% tretinoin, and 22% (13 of 58 subjects) with vehicle. Local adverse events, although more frequent with Tazarotene at higher concentrations, were generally mild to moderate. Conclusions Tazarotene in a cream formulation is safe and is associated with positive changes in the treatment of photodamaged facial skin.
-
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
Journal of the American Academy of Dermatology, 1998Co-Authors: M G Lebwohl, Mark Ling, D L Breneman, B S Goffe, J R Grossman, J Milbauer, S H Pincus, R G Sibbald, L J Swinyer, Gerald D. WeinsteinAbstract:Abstract Background: Topical corticosteroids are often used in the treatment of psoriasis, but long-term use may be associated with serious adverse events such as tachyphylaxis or atrophy of the skin. Tazarotene, a new topical retinoid, has demonstrated significant clinical benefits but can cause mild to moderate local irritation. Objective: We evaluate whether a combination treatment of topical Tazarotene and a topical corticosteroid would increase efficacy while reducing the incidence of local adverse events associated with a topical retinoid. Methods: Three hundred patients enrolled in an investigator-masked study were randomly assigned to 1 of 4 treatment groups: Tazarotene 0.1% gel in combination with placebo cream, or with a low-, mid-, or high-potency corticosteroid cream, for 12 weeks of treatment and a posttreatment follow-up at week 16. Results: Tazarotene 0.1% gel in combination with a mid- or high-potency corticosteroid, when compared with Tazarotene plus placebo cream, achieved significantly greater reductions in scaling, erythema, and overall lesional severity, and a decreased incidence of adverse events. Conclusion: All Tazarotene combinations (including Tazarotene plus placebo) were highly effective in rapidly reducing the severity of psoriasis. Combining Tazarotene with a topical corticosteroid increased efficacy while reducing the incidence of local adverse events. (J Am Acad Dermatol 1998;39:590-6.)
-
The safety and efficacy of Tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
Archives of dermatology, 1998Co-Authors: Gerald G. Krueger, John Sefton, Nicholas J. Lowe, Gerald D. Weinstein, John C Lue, Lynn A. Drake, Peter M. Elias, Cynthia Guzzo, Deborah A. Lew-kaya, Roshantha A. S. ChandraratnaAbstract:Objective To determine the safety and efficacy of topically applied Tazarotene gel in the treatment of mild to moderate psoriatic plaques. Design Two multicenter, double-blind, randomized studies of 6- and 8-week duration, with an 8-week follow-up in the second study. Setting Medical center outpatient dermatology services. Participants One hundred fifty-three adults with 2 bilateral target plaques on the trunk, legs, or arms. Interventions Vehicle gel or 0.01% and 0.05% Tazarotene gel administered twice daily to 45 patients (study A), or 0.05% and 0.1% Tazarotene gel administered either once or twice daily to 108 patients (study B). Main Outcome Measures Treatment success and plaque elevation, scaling, and erythema vs time. Results The 0.01% Tazarotene gel showed minimal efficacy. Applications of 0.05% and 0.1% Tazarotene gels administered once or twice daily, resulted in significant improvements in plaque elevation, scaling, erythema, and overall clinical severity as early as 1 week. Treatment success rates (defined as >75% improvement from baseline) were 45% with 0.05% Tazarotene gel vs 13% with vehicle gel after 6 weeks of treatment ( P Conclusion The 0.05% and 0.1% Tazarotene gels demonstrated significant efficacy in the treatment of mild to moderate psoriatic plaques that persisted after cessation of treatment.
-
Tazarotene gel a new retinoid for topical therapy of psoriasis vehicle controlled study of safety efficacy and duration of therapeutic effect
Journal of The American Academy of Dermatology, 1997Co-Authors: Gerald D. Weinstein, Nicholas J. Lowe, Gerald G. Krueger, Eduardo Tschen, Madeleine Duvic, David J Friedman, Brian V Jegasothy, Joseph L Jorizzo, Edward Shmunes, Deborah A LewkayaAbstract:Abstract Background: Topical therapy providing initial improvement and maintenance of effect after treatment of the large majority of patients with limited, mild to moderate psoriasis is not presently available. Previous topical retinoids have generally been either ineffective or too irritating for therapy of psoriasis. Objective: Our purpose was to evaluate a new topical retinoid, Tazarotene, in the treatment of stable plaque psoriasis during treatment and posttreatment periods. Methods: In a double-blind manner, 324 patients were randomly selected to receive Tazarotene 0.1% or 0.05% gel, or vehicle control, once daily for 12 weeks and were then followed up for 12 weeks after treatment. Results: Of the total, 318 patients could be evaluated. Tazarotene gels were superior ( p Conclusion: Once-daily Tazarotene was effective and safe as a topical monotherapy for plaque psoriasis, providing rapid reduction of signs and symptoms. (J Am Acad Dermatol 1997;37:85–92.)
John Sefton - One of the best experts on this subject based on the ideXlab platform.
-
A multicenter, randomized, double-blind trial of Tazarotene 0.1% cream in the treatment of photodamage.
Journal of The American Academy of Dermatology, 2005Co-Authors: Sewon Kang, Deborah A. Lew-kaya, Patricia S. Walker, John Sefton, Emil Tanghetti, Gerald G. Krueger, John R. GibsonAbstract:Background Previous studies indicate that Tazarotene is efficacious in reducing signs of photodamage. Objective We sought to confirm the efficacy and tolerability of Tazarotene 0.1% cream in the treatment of facial photodamage. Methods A total of 568 patients with at least moderate fine wrinkling or mottled hyperpigmentation applied Tazarotene 0.1% cream or vehicle cream to their face once daily for 24 weeks. Results Tazarotene cream was significantly more effective than vehicle in reducing fine wrinkles, mottled hyperpigmentation, lentigines, irregular depigmentation, apparent pore size, elastosis, tactile roughness, and an overall integrated assessment of photodamage. Significance was achieved as early as week 2 for some parameters and had not plateaued by week 24. The majority of patients reported improvements in their photodamage as early as week 4. Adverse events were predominantly mild or moderate signs or symptoms of skin irritation. Conclusion Once-daily Tazarotene 0.1% cream is effective in ameliorating multiple signs of facial photodamage.
-
Histological effects of Tazarotene 0·1% cream vs. vehicle on photodamaged skin: a 6-month, multicentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin
British Journal of Dermatology, 2004Co-Authors: L.a. Machtinger, K. Kaidbey, K.h. Loven, T.e. Rist, D.c. Wilson, D.d. Parizadeh, John Sefton, J.m. Holland, P S WalkerAbstract:Summary Background Topical Tazarotene has been shown to offer efficacy in ameliorating multiple effects of photodamage. Objectives To evaluate the histological effects of Tazarotene cream on photodamaged skin. Methods In this multicentre, double-blind, randomized, vehicle-controlled study, 50 patients with photodamaged facial skin (at least mild fine wrinkling and mottled hyperpigmentation, with at least one of these being moderate) were randomized to apply Tazarotene 0·1% cream or vehicle cream to their face, once daily for 24 weeks. Results Blinded assessments showed that Tazarotene was less likely than vehicle to be associated with an increase in keratinocytic and melanocytic atypia, and more likely than vehicle to be associated with a reduction in atypia. Between-group comparisons in distribution of change from baseline categories of severity were in favour of Tazarotene (P = 0·055 for keratinocytic atypia, P = 0·034 for melanocytic atypia, and P
-
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of Tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Journal of the American Academy of Dermatology, 2003Co-Authors: Gerald D. Weinstein, John R. Gibson, John Sefton, Nicholas J. Lowe, Gerald G. Krueger, M G Lebwohl, John Koo, Deborah A. Lew-kaya, M. Alan Menter, Patricia S. WalkerAbstract:Abstract Background: Tazarotene in a gel formulation is widely used in the treatment of psoriasis. Objective: To determine the efficacy and safety of Tazarotene 0.1% and 0.05% creams in the treatment of psoriasis. Methods: A total of 1303 patients participated in 2 clinical trials. Patients applied Tazarotene creams 0.1% and 0.05% or vehicle once daily to all psoriatic lesions for 12 weeks followed by a 12-week posttreatment period. Results: Both creams were significantly more effective than vehicle on the basis of an overall assessment of psoriasis, a global response to treatment, and reduction in plaque elevation and scaling. Therapeutic effect was maintained during the posttreatment period. Common adverse events included signs and symptoms of skin irritation. Conclusion: Tazarotene creams were associated with significant reductions in the severity of the clinical signs of psoriasis and were found to be safe with acceptable tolerability. Tazarotene cream 0.1% was generally more effective, although slightly less well tolerated, than the 0.05% cream. (J Am Acad Dermatol 2003;48:760-7.)
-
efficacy of 0 1 Tazarotene cream for the treatment of photodamage a 12 month multicenter randomized trial
Archives of Dermatology, 2002Co-Authors: Tania J Phillips, Deborah A Lewkaya, Patricia S. Walker, John Sefton, Alice B. Gottlieb, James J. Leyden, Nicholas J. Lowe, John R. GibsonAbstract:Objective To determine the efficacy and safety of 0.1% Tazarotene cream for the treatment of photodamage. Design A 24-week multicenter, double-blind, randomized, vehicle-controlled intervention study followed by a 28-week open-label extension. Setting Ambulatory patients in private and institutional practice. Patients Of 563 patients with facial photodamage, 91% and 86% completed the double-blind and open-label phases, respectively. In the double-blind phase, 20 of 283 Tazarotene-treated patients and 1 of 280 vehicle-treated patients discontinued treatment owing to adverse events. Intervention Once-daily application of 0.1% Tazarotene cream or nonmedicated vehicle cream to the face for 24 weeks. Then, all continuing patients received treatment with 0.1% Tazarotene cream for another 28 weeks. Main Outcome Measures Primarily, fine wrinkling and mottled hyperpigmentation. Also, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, telangiectasia, actinic keratoses, overall integrated assessment of photodamage, global response to treatment, patients' overall assessment of photodamage, and plasma levels of tazarotenic acid. Results Compared with the vehicle, at week 24 Tazarotene resulted in a significantly greater incidence of patients achieving treatment success (≥50% global improvement) and at least a 1-grade improvement in fine wrinkling, mottled hyperpigmentation, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, and the overall integrated assessment of photodamage ( P Conclusions Once-daily applications of 0.1% Tazarotene cream significantly reduced multiple signs of photodamage. Plasma levels of tazarotenic acid remained below those of endogenous retinoids.
-
A pilot study to determine the effect of Tazarotene gel 0.1% on steroid-induced epidermal atrophy.
International journal of dermatology, 2001Co-Authors: Kays Kaidbey, John Sefton, Scott C. Kopper, John R. GibsonAbstract:Background Repeated applications of a corticosteroid can induce epidermal atrophy. This study was performed to investigate whether the adjunctive use of Tazarotene gel 0.1% might help to minimize the development of steroid-induced epidermal atrophy. Methods Each of 24 healthy volunteers received the following six treatments (applied 6 days per week for 4 weeks), which were randomized to each of six sites on their forearms: no treatment, Tazarotene vehicle, Tazarotene vehicle + Tazarotene gel 0.1%, diflorasone diacetate 0.05% ointment, diflorasone diacetate 0.05% ointment + Tazarotene vehicle, or diflorasone diacetate 0.05% ointment + Tazarotene gel 0.1%. Results The mean epidermal thickness was increased by 20% (NS) and 62% (P ≤ 0.0005) after applications of Tazarotene vehicle and Tazarotene gel 0.1%, respectively. Application of diflorasone diacetate reduced the mean epidermal thickness by 43% (P ≤ 0.0005). Concomitant application of Tazarotene gel 0.1% with diflorasone diacetate did not entirely prevent atrophy, but was shown to ameliorate 37% of the epidermal atrophy induced by diflorasone diacetate alone (P ≤ 0.003 compared with steroid monotherapy). Conclusions Tazarotene gel 0.1% significantly reduces epidermal atrophy induced by diflorasone diacetate 0.05% ointment.
Nicholas J. Lowe - One of the best experts on this subject based on the ideXlab platform.
-
Tazarotene versus Tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study.
Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 2006Co-Authors: Nicholas J. Lowe, Emil Tanghetti, Zoe Diana Draelos, Stephen Horwitz, Alan MenterAbstract:Objectives: To compare the efficacy and tolerability of Tazarotene plus hydroquinone versus Tazarotene alone in the treatment of facial photodamage. Methods: Patients with facial mottled hyperpigmentation of at least moderate severity and an overall integrated assessment of photodamage score of at least moderate applied Tazarotene 0.1% cream each evening and either hydroquinone 4% cream or placebo cream each morning for up to 24 weeks. Results: Among 131 patients enrolled, 114/124 (92%) with exit data completed. Both regimens were highly effective in reducing photodamage, with Tazarotene plus hydroquinone showing superiority over Tazarotene alone for some efficacy measures. The incidence of ⩾1‐grade improvement from baseline (on a scale of none, minimal, mild, moderate, or severe) was significantly greater with Tazarotene plus hydroquinone than with Tazarotene alone for lentigines (weeks 12–24, p⩽0.01) and mottled hyperpigmentation (week 16, p⩽0.05). The incidence of ⩾50% global improvement was also signi...
-
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of Tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Journal of the American Academy of Dermatology, 2003Co-Authors: Gerald D. Weinstein, John R. Gibson, John Sefton, Nicholas J. Lowe, Gerald G. Krueger, M G Lebwohl, John Koo, Deborah A. Lew-kaya, M. Alan Menter, Patricia S. WalkerAbstract:Abstract Background: Tazarotene in a gel formulation is widely used in the treatment of psoriasis. Objective: To determine the efficacy and safety of Tazarotene 0.1% and 0.05% creams in the treatment of psoriasis. Methods: A total of 1303 patients participated in 2 clinical trials. Patients applied Tazarotene creams 0.1% and 0.05% or vehicle once daily to all psoriatic lesions for 12 weeks followed by a 12-week posttreatment period. Results: Both creams were significantly more effective than vehicle on the basis of an overall assessment of psoriasis, a global response to treatment, and reduction in plaque elevation and scaling. Therapeutic effect was maintained during the posttreatment period. Common adverse events included signs and symptoms of skin irritation. Conclusion: Tazarotene creams were associated with significant reductions in the severity of the clinical signs of psoriasis and were found to be safe with acceptable tolerability. Tazarotene cream 0.1% was generally more effective, although slightly less well tolerated, than the 0.05% cream. (J Am Acad Dermatol 2003;48:760-7.)
-
efficacy of 0 1 Tazarotene cream for the treatment of photodamage a 12 month multicenter randomized trial
Archives of Dermatology, 2002Co-Authors: Tania J Phillips, Deborah A Lewkaya, Patricia S. Walker, John Sefton, Alice B. Gottlieb, James J. Leyden, Nicholas J. Lowe, John R. GibsonAbstract:Objective To determine the efficacy and safety of 0.1% Tazarotene cream for the treatment of photodamage. Design A 24-week multicenter, double-blind, randomized, vehicle-controlled intervention study followed by a 28-week open-label extension. Setting Ambulatory patients in private and institutional practice. Patients Of 563 patients with facial photodamage, 91% and 86% completed the double-blind and open-label phases, respectively. In the double-blind phase, 20 of 283 Tazarotene-treated patients and 1 of 280 vehicle-treated patients discontinued treatment owing to adverse events. Intervention Once-daily application of 0.1% Tazarotene cream or nonmedicated vehicle cream to the face for 24 weeks. Then, all continuing patients received treatment with 0.1% Tazarotene cream for another 28 weeks. Main Outcome Measures Primarily, fine wrinkling and mottled hyperpigmentation. Also, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, telangiectasia, actinic keratoses, overall integrated assessment of photodamage, global response to treatment, patients' overall assessment of photodamage, and plasma levels of tazarotenic acid. Results Compared with the vehicle, at week 24 Tazarotene resulted in a significantly greater incidence of patients achieving treatment success (≥50% global improvement) and at least a 1-grade improvement in fine wrinkling, mottled hyperpigmentation, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, and the overall integrated assessment of photodamage ( P Conclusions Once-daily applications of 0.1% Tazarotene cream significantly reduced multiple signs of photodamage. Plasma levels of tazarotenic acid remained below those of endogenous retinoids.
-
Tazarotene cream for the treatment of facial photodamage a multicenter investigator masked randomized vehicle controlled parallel comparison of 0 01 0 025 0 05 and 0 1 Tazarotene creams with 0 05 tretinoin emollient cream applied once daily for 24 we
Archives of Dermatology, 2001Co-Authors: Sewon Kang, Jean-paul Ortonne, Tania J Phillips, Deborah A Lewkaya, James J. Leyden, Nicholas J. Lowe, Jag Bhawan, Gerald D. Weinstein, Richard M MatsumotoAbstract:Objective To assess the safety and efficacy of 4 concentrations of Tazarotene cream in the treatment of facial photodamage. Design Prospective weekly multicenter, investigator-masked, randomized, parallel-group study. Setting University hospitals and clinical research centers. Patients Three hundred forty-nine subjects with facial photodamage. Intervention Daily topical application of Tazarotene cream (0.01%, 0.025%, 0.05%, and 0.1%) compared with its vehicle and with 0.05% tretinoin emollient cream. Results Tazarotene cream and tretinoin cream significantly improved mottled hyperpigmentation and fine wrinkles. At week 24, treatment success rates based on global responses were 67% (39 of 58 subjects) with 0.1% Tazarotene, 52% (30 of 58 subjects) with 0.05% Tazarotene, 36% (21 of 58 subjects) with 0.025% Tazarotene, 41% (24 of 59 subjects) with 0.01% Tazarotene, 55% (32 of 58 subjects) with 0.05% tretinoin, and 22% (13 of 58 subjects) with vehicle. Local adverse events, although more frequent with Tazarotene at higher concentrations, were generally mild to moderate. Conclusions Tazarotene in a cream formulation is safe and is associated with positive changes in the treatment of photodamaged facial skin.
-
comparison of treatment of acne vulgaris with alternate day applications of Tazarotene 0 1 gel and once daily applications of adapalene 0 1 gel a randomized trial
Cutis, 2001Co-Authors: James J. Leyden, Nicholas J. Lowe, L Kakita, Zoe Diana DraelosAbstract:Tazarotene and adapalene are recently introduced topical retinoids that are useful in the treatment of acne vulgaris. The clinical benefits of each drug have now been compared in a multicenter, double-blind, randomized, parallel-group study involving 164 patients with mild-to-moderate facial acne vulgaris. Patients were randomized to receive 15 weeks' treatment with alternate-day Tazarotene 0.1% gel, with vehicle gel on the intervening evenings, or once-daily adapalene 0.1% gel. Both regimens were comparably effective with no significant between-group differences in efficacy measures. A total of 74% of Tazarotene-treated subjects and 73% of adapalene-treated subjects achieved at least a 50% improvement in their acne. In addition, there were no clinically significant differences in tolerability. It is concluded that an alternate-day Tazarotene regimen offers efficacy and thus Tazarotene treatment can be useful even in patients whose compliance may be suboptimal. An alternate-day regimen also offers the potential for considerable savings in drug costs.
